Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...
Biotech giant Amgen (NASDAQ: AMGN) isn't starting the year on a strong note. The company's shares are down by 5% since Jan. 1. It has dealt with some issues lately, especially subpar financial ...
Boehringer Ingelheim on Thursday said it will lay off some of its salesforce due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira. The German drugmaker ...
Novartis plans to cut as many as 680 jobs in development, Sanofi's pipeline reprioritization project will result in layoffs.
Due to slow uptake of its Humira biosimilar Cyltezo in the U.S., Boehringer Ingelheim is laying off an undisclosed number of ...
Pfizer announced Tuesday it would lay off up to 800 researchers, according to a report from 'The Wall Street Journal.' Pfizer expects to have laid off 5% to 8% of its 10,000-person research staff ...
Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity ...
Last year Stellantis offered buyout and early retirement packages to about 6,400 nonunion salaried workers, but it has not said how many took the offers. Jeep maker Stellantis is laying off about ...
J.D. DURKIN: Coinbase (COIN) announcing plans here, Martin, to 20% of its workforce, marking the second round of job cuts for that company alone. What do we know with regards to the details?
Amgen has been struggling to grow its revenue at a good clip organically. The company's pipeline and a recent acquisition should help it improve. The biotech is an excellent stock for income ...